Autonomix Medical Granted New U.S. Patent Strengthening Proprietary Catheter-Based Sensing Technology
Key Highlights
- ➤U.S. Patent No. 12,793,841 expands protection for Autonomix’s catheter-based sensing technology
- ➤Patent covers near-source physiological signal capture and processing for real-time monitoring
- ➤Architecture features distributed processing, configurable sensing and efficient data transmission
- ➤Technology remains investigational and has not received U.S. marketing clearance
Expert Statements
Brad Hauser, Chief Executive Officer of Autonomix Medical
“This latest patent further strengthens the intellectual property foundation supporting our proprietary sensing technology and reinforces our commitment to advancing precision nerve-targeted interventions.”
Brad Hauser, Chief Executive Officer of Autonomix Medical
“Our ability to capture and process physiological signals directly at their source represents what we believe is a key differentiator of our platform.”
Brad Hauser, Chief Executive Officer of Autonomix Medical
“We believe this technology has the potential to provide physicians with greater insight into neural activity and support more precise, informed treatment decisions across a broad range of clinical applications.”
Latest patent expands intellectual property protection for advanced physiological signal acquisition and processing
THE WOODLANDS, TX, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,793,841, titled “Medical Devices With Circuitry For Capturing And Processing Physiological Signals,” further strengthening the Company's intellectual property portfolio supporting its proprietary catheter-based sensing technology.
Get started
Create a free account to read the full story.